Aarti Pharmalabs Ltd
NSE: AARTIPHARM BSE: 543748
₹863.80
-3.85 (0.44%)
Fri, 23 Oct 2026, 00:05 pm
Market Cap (in Cr)7856.5
PE Ratio36.75
Dividend0.40
Health Technology
Pharmaceuticals: Major
24.5KAarti Pharmalabs Financials
| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Total revenue | 0 | 11.94B | 19.38B | 18.18B | 20.88B |
| Gross profit | 0 | 1.92B | 4.07B | 3.93B | 5.49B |
| Operating expenses (excl. COGS) | -45.96K | -335.82M | -1.33B | -1.12B | -1.94B |
| Selling/general/admin expenses, total | -45.96K | -335.75M | -1.32B | -1.09B | -1.91B |
| Research & development | — | -58.16M | -139.60M | -83.70M | -328.32M |
| Selling/general/admin expenses, other | -45.96K | -277.60M | -1.18B | -1.00B | -1.58B |
| Other operating expenses, total | 0 | -70.00K | -10.73M | -31.88M | -37.49M |
| Operating income | -45.96K | 1.59B | 2.74B | 2.81B | 3.55B |
| Non-operating income, total | 0 | -33.47M | -128.27M | 189.99M | 57.12M |
| Interest expense, net of interest capitalized | 0 | -119.59M | -210.52M | -172.15M | -268.96M |
| Interest capitalized | 0 | 0 | 0 | 0 | 0 |
| Non-operating income, excl. interest expenses | 0 | 86.12M | 82.25M | 362.14M | 326.08M |
| Non-operating interest income | 0 | 57.00K | 9.37M | 30.42M | 70.96M |
| Miscellaneous non-operating expense | 0 | 86.06M | 72.88M | 331.72M | 255.12M |
| Unusual income/expense | — | 0 | 0 | 0 | 0 |
| Pretax income | -45.96K | 1.55B | 2.61B | 3.00B | 3.61B |
| Taxes | 0 | -331.29M | -672.81M | -835.90M | -882.85M |
| Non-controlling/minority interest | 0 | 0 | 0 | 0 | 0 |
| After tax other income/expense | 0 | 0 | 0 | 0 | 0 |
| Net income before discontinued operations | -45.96K | 1.22B | 1.93B | 2.17B | 2.72B |
| Net income | -45.96K | 1.22B | 1.93B | 2.17B | 2.72B |
| Dilution adjustment | 0 | 0 | 0 | 0 | 0 |
| Preferred dividends | 0 | 0 | 0 | 0 | 0 |
| Diluted net income available to common stockholders | -45.96K | 1.22B | 1.93B | 2.17B | 2.72B |
| Basic earnings per share (Basic EPS) | - | - | - | - | - |
| Diluted earnings per share (Diluted EPS) | - | - | - | - | - |
| EBITDA | -45.96K | 2.01B | 3.36B | 3.55B | 4.42B |
| EBIT | -45.96K | 1.59B | 2.74B | 2.81B | 3.55B |
| Total operating expenses | -45.96K | -10.35B | -16.65B | -15.37B | -17.33B |
| Prepaid expenses | — | 41.95M | 23.25M | 61.48M | 63.44M |
| Deferred income, current | — | — | — | — | 9.44M |
| Capital and operating lease obligations | 0 | 5.32M | 166.59M | 166.59M | 116.69M |
| Operating lease liabilities | — | — | — | — | — |
| Deferred tax liabilities | — | 706.70M | 807.90M | 1.09B | 1.31B |
| Deferred income, non-current | — | — | — | — | — |
| Minority interest | 0 | 0 | 0 | 0 | 0 |
| Change in accrued expenses | — | — | — | — | — |
| Common dividends paid | 0 | 0 | -181.25M | -181.25M | -317.19M |
| Preferred dividends paid | 0 | 0 | 0 | 0 | 0 |
